Tertiles | ||||||
---|---|---|---|---|---|---|
1 | 2 | 3 | ||||
Cut points (ng/mL) | <0.18 | 0.18 - <0.22 | ≥0.22 | p trend a | RRlog2 c | p het d |
Hormone receptor positive cases | ||||||
Premenopausal | ||||||
ER+/PR+ | ||||||
Cases/controls | 168/152 | 61/77 | 24/24 | |||
RR (95% CI) | Ref. | 0.67 (0.43-1.04) | 0.89 (0.42-1.87) | 0.07 | 0.58 (0.32-1.05) | 0.36 |
ER+ | ||||||
Cases/controls | 236/200 | 79/118 | 37/34 | |||
RR (95% CI) | Ref. | 0.55 (0.38-0.81) | 0.85 (0.47-1.55) | 0.01b | 0.53 (0.31-0.88) b | 0.05 b |
Postmenopausal | ||||||
ER+/PR+ | ||||||
Cases/controls | 174/160 | 236/231 | 266/285 | |||
RR (95% CI) | Ref. | 0.92 (0.68-1.24) | 0.85 (0.61-1.17) | 0.73 | 0.94 (0.66-1.33) | |
ER+ | ||||||
Cases/controls | 323/310 | 440/426 | 507/534 | |||
RR (95% CI) | Ref. | 0.98 (0.78-1.22) | 0.91 (0.72-1.15) | 0.79 | 0.97 (0.75-1.25) | |
Hormone receptor negative cases | ||||||
Premenopausal | ||||||
ER–/PR– | ||||||
Cases/controls | 35/44 | 18/17 | 14/6 | |||
RR (95% CI) | Ref. | 1.60 (0.57-4.44) | 3.77 (0.86-16.4) | 0.25 | 2.01 (0.60-6.70) | 0.87 |
ER– | ||||||
Cases/controls | 59/70 | 30/30 | 21/10 | |||
RR (95% CI) | Ref. | 1.42 (0.67-2.99) | 3.21 (1.17-8.85) | 0.26 | 1.63 (0.70-3.84) | 0.97 |
Postmenopausal | ||||||
ER–/PR– | ||||||
Cases/controls | 47/52 | 60/79 | 84/60 | |||
RR (95% CI) | Ref. | 1.02 (0.55-1.89) | 2.03 (1.03-3.98) | 0.14 | 1.76 (0.82-3.77) | |
ER– | ||||||
Cases/controls | 80/90 | 87/95 | 109/91 | 0.12 | 1.62 (0.88-2.96) | |
RR (95% CI) | Ref. | 1.14 (0.68-1.90) | 1.60 (0.95-2.69) |